Please assess the completion status of the following clinical trial:

Trial Title: Thromboprophylaxis of Venous Thromboembolism in Acutely-ill Medical Inpatients With Thrombocytopenia

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Age above 18 years;~* hospitalization in an Internal Medicine Unit and a Barbar score of 4 points or above~* Platelet count between 100,000/uL and 30,000/uL~* written informed consent~Exclusion Criteria:~* Active bleeding or bleeding within the previous 3 months;~* Known bleeding diathesis;~* Active gastroduodenal ulcer;~* Severe renal insufficiency defined by a creatinine clearance below 20 mL/min;~* Ongoing treatment with unfractionated heparin, low-moleculr-weight heparin, fondaparinux, or oral anticoagulants Trattamento in corso con eparina non~* Prophylaxis with unfractionated heparin, low-moleculr-weight heparin, or fondaparinux for more than 48 hours;~* double antiplatelet therapy or acetylsalicylic acid at daily doses above 165 mg;~* planned invasive procedure during the period of thromboprophylaxis;~* Hemoglobin values below 9 g/dL;~* AST or ALT above 2 times the uper limit of normal;~* pregnancy or breast feeding;~* life expectancy lower than 1 month

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Fondaparinux (Type: EXPERIMENTAL): Drug: fondaparinux once daily sc injections 2.5 mg if renal clearance of creatinine above 50 ml/min once daily sc injections 1.5 mg if renal clearance of creatinine between 20 and 50 ml/min

Based on this trial design, predict the completion outcome and termination type (if applicable).